Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001969764-25-000003·Milestone Pharmaceuticals Inc.
Schedule 13G ownership disclosure
MILESTONE PHARMACEUTICALS IN
Common Stock · CUSIP: 59935V107
Event date: 2025-07-11
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Propel Bio Management, LLC
Shares: 8,861,186.00 · Class: 9.9%
- Leen Kawas
Shares: 8,861,186.00 · Class: 9.9%
- Richard Kayne
Shares: 8,861,186.00 · Class: 9.9%
- Propel Bio Partners LLC
Shares: 8,861,186.00 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001969764-25-000003
- Form type
- SCHEDULE 13G
- Filer
- Milestone Pharmaceuticals Inc.
- CIK
- CIK 1408443
- Filed
- Dec 23, 2025
- Reporting period
- Jul 11, 2025
- Description
- Schedule 13G beneficial ownership